Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28772799 | 0.98 | ALDH1A1 (0.31) | ALDH1A1 | |
| SCHEMBL13726323 | 0.80 | TRPA1 (0.37) | ALDH1A1 | |
| SCHEMBL2155974 | 0.79 | ALDH1A1 (0.34) | ALDH1A1 | |
| SCHEMBL26914801 | 0.78 | — | — | |
| SCHEMBL10768642 | 0.76 | MEN1 (0.31) | ALDH1A1 | |
| SCHEMBL11526486 | 0.74 | TAS2R14 (0.38) | — | |
| SCHEMBL11110746 | 0.73 | RAB9A (0.31) | ALDH1A1 | |
| SCHEMBL11021176 | 0.73 | RAB9A (0.31) | ALDH1A1 | |
| SCHEMBL11522076 | 0.71 | ACHE (0.42) | ALDH1A1 | |
| SCHEMBL15404199 | 0.70 | TDP1 (0.56) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090124607-A1 | Novel Bicyclic Sulfonamides for Use as Glucocorticoid Receptor Modulators in the Treatment of Inflammatory Diseases | ASTRAZENECA AB (SE) | 2009-05-14 | — | — | US | disclosed |
| EP-1940800-A1 | NOVEL BICYCLIC SULFONAMIDES FOR USE AS GLUCOCORTICOID RECEPTOR MODULATORS IN THE TREATMENT OF INFLAMMATORY DISEASES | Astra Zeneca AB (SE) | 2008-07-09 | — | — | EP | disclosed |
| WO-2007046747-A1 | NOVEL BICYCLIC SULFONAMIDES FOR USE AS GLUCOCORTICOID RECEPTOR MODULATORS IN THE TREATMENT OF INFLAMMATORY DISEASES | ASTRAZENECA AB (SE) | 2007-04-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090124607-A1 | Novel Bicyclic Sulfonamides for Use as Glucocorticoid Receptor Modulators in the Treatment of Inflammatory Diseases | NR3C1, NR3C2, MC2R | ALDH1A1 2378/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.